Objective:To reveal the molecular characteristics of gene fusions in gastric cancer and their potential targeted therapeutic value, and to develop new targeted treatment strategies for advanced gastric cancer.Methods:Tumor tissue samples from 50 fusion-positive gastric cancer patients admitted to the Zhejiang Provincial People′s Hospital from January 2018 to December 2024 were retrospectively included. Next-generation sequencing (NGS) technologies for DNA and RNA were used to analyze gene fusion events in these 50 patients.Results:A total of 53 gene fusion events were detected in the 50 gastric cancer samples, among which 73.6%(39) were druggable fusion types. The main types included FGFR (25.6%, 10/39), NTRK (15.4%, 6/39), MET (12.8%, 5/39), and ROS1 (12.8%, 5/39). Further verification by RNA NGS showed that some gene fusion events could not be confirmed at the transcript level, indicating that there was a certain false positive rate in DNA-level detection. Conclusions:This study provides new molecular targets for personalized targeted therapy of gastric cancer, especially new clinical application prospects for targeted therapy of genes such as FGFR, NTRK, MET, and ROS1. It also emphasizes the importance of RNA NGS in the detection of gene fusions in gastric cancer, which can effectively supplement and correct the false positive signals of DNA NGS and further improve the detection accuracy.

Objective:To reveal the molecular characteristics of gene fusions in gastric cancer and their potential targeted therapeutic value, and to develop new targeted treatment strategies for advanced gastric cancer.Methods:Tumor tissue samples from 50 fusion-positive gastric cancer patients admitted to the Zhejiang Provincial People′s Hospital from January 2018 to December 2024 were retrospectively included. Next-generation sequencing (NGS) technologies for DNA and RNA were used to analyze gene fusion events in these 50 patients.Results:A total of 53 gene fusion events were detected in the 50 gastric cancer samples, among which 73.6%(39) were druggable fusion types. The main types included FGFR (25.6%, 10/39), NTRK (15.4%, 6/39), MET (12.8%, 5/39), and ROS1 (12.8%, 5/39). Further verification by RNA NGS showed that some gene fusion events could not be confirmed at the transcript level, indicating that there was a certain false positive rate in DNA-level detection. Conclusions:This study provides new molecular targets for personalized targeted therapy of gastric cancer, especially new clinical application prospects for targeted therapy of genes such as FGFR, NTRK, MET, and ROS1. It also emphasizes the importance of RNA NGS in the detection of gene fusions in gastric cancer, which can effectively supplement and correct the false positive signals of DNA NGS and further improve the detection accuracy.

OBJECTIVETo explore the NEK-6 expression in gastric cancer tissue and its relationship with clinicopathological features.

METHODSFluorescent quantification PCR and Western blotting were used to examine the NEK-6 expression in 36 samples of fresh gastric cancer tissues and para-cancer gastric mucosal tissues, human gastric cancer cell lines(BGC-823, MKN-28, SGC-7901, MGC-803, HGC-27, AGS), and human normal gastric epithelial cell line (GES-1). Gastric cancer cell lines with the highest expression level were selected to perform the invasion and migration tests, and the effect of down-regulated NEK-6 expression by siRNA transfection on above invasion and migration tests were observed. Meanwhile NEK-6 expression in 94 paraffin samples of gastric cancer tissues was examined by immunohistochemistry and its positivity was compared among different clinicopathologic features.

RESULTSFluorescent quantification PCR revealed gastric cancer tissues had significantly higher NEK-6 expression than para-cancer tissues(0.002 80±0.001 36 vs. 0.001 91±0.001 48, P<0.05), NEK-6 expression was up-regulated in 31 gastric cancer tissues (86.1%), and human gastric cancer cell lines had significantly higher NEK-6 expression than GES-1 cells, among whom BGC-823 and AGS cell lines were the highest. Invasion and migration tests showed that as compared to negative siRNA control group, ability of invasion and migration in BGC-823 and AGS cells after siRNA transfection was obviously decreased. In 94 paraffin samples, positive expression rate of NEK-6 was 60.6%(57/94), and NEK-6 expression was significantly associated with gastric cancer distant metastasis, lymph nodes metastasis and TNM staging(all P<0.05).

CONCLUSIONSNEK-6 expression is up-regulated in gastric cancer tissues, which is significantly associated with distant metastasis, lymph nodes metastasis and TNM staging. Down-regulation of NEK-6 expression can inhibit the ability of invasion and migration in gastric cancer cells.

Humans ; Leukemia, Lymphocytic, Chronic, B-Cell ; complications ; Stomach Neoplasms ; complications

Nowadays more and more biologists and immunologists focus on Galectin-1 due to the in -depth study of Galectins.As one of the important member of Galectins,Galectin-1 distributes widely,exists in a variety of tissues and cells,involves in cell adhesion,proliferation,apoptosis and inflammatory reaction,and results in a variety of physiological and pathological process.Recent studies have found that Galectin-1 expression in a variety of malignant tumor with a close relationship with tumor occurrence,invasion,development,anti-tumor immunity,and metastasis.It may be a potentially new target for cancer and inflammation therapies.This present paper reviews the current research about Galectin-1 and tumor progression.

Objective To explore the NEK-6 expression in gastric cancer tissue and its relationship with clinicopathological features. Methods Fluorescent quantification PCR and Western blotting were used to examine the NEK-6 expression in 36 samples of fresh gastric cancer tissues and para-cancer gastric mucosal tissues, human gastric cancer cell lines ﹙BGC-823, MKN-28, SGC-7901, MGC-803, HGC-27, AGS), and human normal gastric epithelial cell line ﹙GES-1). Gastric cancer cell lines with the highest expression level were selected to perform the invasion and migration tests, and the effect of down-regulated NEK-6 expression by siRNA transfection on above invasion and migration tests were observed. Meanwhile NEK-6 expression in 94 paraffin samples of gastric cancer tissues was examined by immunohistochemistry and its positivity was compared among different clinicopathologic features. Results Fluorescent quantification PCR revealed gastric cancer tissues had significantly higher NEK-6 expression than para-cancer tissues ﹙0.002 80 ±0.001 36 vs. 0.001 91 ±0.001 48, P<0.05), NEK-6 expression was up-regulated in 31 gastric cancer tissues ﹙86.1%), and human gastric cancer cell lines had significantly higher NEK-6 expression than GES-1 cells, among whom BGC-823 and AGS cell lines were the highest. Invasion and migration tests showed that as compared to negative siRNA control group, ability of invasion and migration in BGC-823 and AGS cells after siRNA transfection was obviously decreased. In 94 paraffin samples, positive expression rate of NEK-6 was 60.6%﹙57/94),and NEK-6 expression was significantly associated with gastric cancer distant metastasis, lymph nodes metastasis and TNM staging ﹙all P<0.05). Conclusions NEK-6 expression is up-regulated in gastric cancer tissues, which is significantly associated with distant metastasis, lymph nodes metastasis and TNM staging. Down-regulation of NEK-6 expression can inhibit the ability of invasion and migration in gastric cancer cells.

Objective To explore the NEK-6 expression in gastric cancer tissue and its relationship with clinicopathological features. Methods Fluorescent quantification PCR and Western blotting were used to examine the NEK-6 expression in 36 samples of fresh gastric cancer tissues and para-cancer gastric mucosal tissues, human gastric cancer cell lines ﹙BGC-823, MKN-28, SGC-7901, MGC-803, HGC-27, AGS), and human normal gastric epithelial cell line ﹙GES-1). Gastric cancer cell lines with the highest expression level were selected to perform the invasion and migration tests, and the effect of down-regulated NEK-6 expression by siRNA transfection on above invasion and migration tests were observed. Meanwhile NEK-6 expression in 94 paraffin samples of gastric cancer tissues was examined by immunohistochemistry and its positivity was compared among different clinicopathologic features. Results Fluorescent quantification PCR revealed gastric cancer tissues had significantly higher NEK-6 expression than para-cancer tissues ﹙0.002 80 ±0.001 36 vs. 0.001 91 ±0.001 48, P<0.05), NEK-6 expression was up-regulated in 31 gastric cancer tissues ﹙86.1%), and human gastric cancer cell lines had significantly higher NEK-6 expression than GES-1 cells, among whom BGC-823 and AGS cell lines were the highest. Invasion and migration tests showed that as compared to negative siRNA control group, ability of invasion and migration in BGC-823 and AGS cells after siRNA transfection was obviously decreased. In 94 paraffin samples, positive expression rate of NEK-6 was 60.6%﹙57/94),and NEK-6 expression was significantly associated with gastric cancer distant metastasis, lymph nodes metastasis and TNM staging ﹙all P<0.05). Conclusions NEK-6 expression is up-regulated in gastric cancer tissues, which is significantly associated with distant metastasis, lymph nodes metastasis and TNM staging. Down-regulation of NEK-6 expression can inhibit the ability of invasion and migration in gastric cancer cells.

OBJECTIVETo study the expression of phospholipase C epsilon-1(PLCE1) and its clinical significance in gastric cancer.

METHODSSurgical specimens were collected from 125 patients who underwent radical gastrectomy between 2005 and 2007 in the Zhejiang Provincial Peoples' Hospital. Expression level of PLCE1 protein was measured by immunohistochemistry in these 125 surgical specimens, which included primary gastric cancer and matched adjacent normal gastric mucosa tissues, and then 41 pairs of above specimens were selected randomly to examine the expression level of PLCE1 mRNA by quantitative reverse transcription PCR(qRT-PCR).

RESULTSImmunohistochemistry and qRT-PCR showed that both protein and mRNA level of PLCE1 were up-regulated in gastric cancer compared with paired normal gastric mucosa. Univariate analysis demonstrated that the expression of PLCE1 was significantly associated with differentiation degree, invasion depth, lymph node metastasis, distant metastasis, and TNM stage (all P<0.01). The 5-year survival rate of positive PLCE1 group was significantly lower as compared to negative group (31.2% vs. 54.0%, P<0.01). However, the expression of PLCE1 was not an independent prognostic factor for gastric cancer (P>0.05).

CONCLUSIONSPLCE1 is up-regulated in gastric cancer, which is associated with the malignant biological behaviors of gastric cancer. High expression of PLCE1 suggests poor prognosis.

Biomarkers, Tumor ; analysis ; Gastrectomy ; Humans ; Immunohistochemistry ; Lymphatic Metastasis ; Neoplasm Staging ; Phosphoinositide Phospholipase C ; metabolism ; Prognosis ; RNA, Messenger ; Reverse Transcriptase Polymerase Chain Reaction ; Stomach Neoplasms ; enzymology ; pathology ; Survival Rate ; Up-Regulation

Objective To study the expression of phospholipase C epsilon-1 (PLCE1) and its clinical significance in gastric cancer. Methods Surgical specimens were collected from 125 patients who underwent radical gastrectomy between 2005 and 2007 in the Zhejiang Provincial Peoples′Hospital. Expression level of PLCE1 protein was measured by immunohistochemistry in these 125 surgical specimens, which included primary gastric cancer and matched adjacent normal gastric mucosa tissues, and then 41 pairs of above specimens were selected randomly to examine the expression level of PLCE1 mRNA by quantitative reverse transcription PCR (qRT-PCR). Results Immunohistochemistry and qRT-PCR showed that both protein and mRNA level of PLCE1 were up-regulated in gastric cancer compared with paired normal gastric mucosa. Univariate analysis demonstrated that the expression of PLCE1 was significantly associated with differentiation degree, invasion depth, lymph node metastasis, distant metastasis, and TNM stage (all P<0.01). The 5-year survival rate of positive PLCE1 group was significantly lower as compared to negative group (31.2%vs. 54.0%, P<0.01). However, the expression of PLCE1 was not an independent prognostic factor for gastric cancer (P>0.05). Conclusions PLCE1 is up-regulated in gastric cancer,which is associated with the malignant biological behaviors of gastric cancer. High expression of PLCE1 suggests poor prognosis.

Objective To study the expression of phospholipase C epsilon-1 (PLCE1) and its clinical significance in gastric cancer. Methods Surgical specimens were collected from 125 patients who underwent radical gastrectomy between 2005 and 2007 in the Zhejiang Provincial Peoples′Hospital. Expression level of PLCE1 protein was measured by immunohistochemistry in these 125 surgical specimens, which included primary gastric cancer and matched adjacent normal gastric mucosa tissues, and then 41 pairs of above specimens were selected randomly to examine the expression level of PLCE1 mRNA by quantitative reverse transcription PCR (qRT-PCR). Results Immunohistochemistry and qRT-PCR showed that both protein and mRNA level of PLCE1 were up-regulated in gastric cancer compared with paired normal gastric mucosa. Univariate analysis demonstrated that the expression of PLCE1 was significantly associated with differentiation degree, invasion depth, lymph node metastasis, distant metastasis, and TNM stage (all P<0.01). The 5-year survival rate of positive PLCE1 group was significantly lower as compared to negative group (31.2%vs. 54.0%, P<0.01). However, the expression of PLCE1 was not an independent prognostic factor for gastric cancer (P>0.05). Conclusions PLCE1 is up-regulated in gastric cancer,which is associated with the malignant biological behaviors of gastric cancer. High expression of PLCE1 suggests poor prognosis.